Cinda Securities released a research report on April 22 stating that it gave Pumen Technology (688389.SH) a buying rating. The main reasons for the rating include: 1) the company's business focuses on the two major sectors of in vitro diagnosis and treatment and rehabilitation; 2) in vitro diagnosis+treatment and rehabilitation business performance was outstanding in 2023; 3) diabetes is one of the chronic diseases with the highest number of patients in China, and the glycated hemoglobin testing market has broad room for development; 4) the share of high added value businesses such as medicine and aesthetics is expected to continue to increase in the future. (Mainichi Keizai Shimbun)
信达证券4月22日发布研报称，给予普门科技（688389.SH）买入评级。评级理由主要包括：1）公司业务聚焦于体外诊断和治疗与康复两大板块；2）体外诊断+治疗康复双轮驱动，2023年治疗康复业务表现亮眼；3）糖尿病是我国患病人数最多的慢性病之一，糖化血红蛋白检测市场发展空间广阔；4）未来医美等高附加值业务占比有望继续提升。（每日经济新闻）
Cinda Securities released a research report on April 22 stating that it gave Pumen Technology (688389.SH) a buying rating. The main reasons for the rating include: 1) the company's business focuses on the two major sectors of in vitro diagnosis and treatm
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.